The Clinical Observation Of Qili Qiangxin Capsule On The Vulnerable Stage Of Heart Failure Patients With Yang-deficiency And Water-sufficiency Syndrome

Purpose:To explore the effect of Qili Qiangxin Capsule on the therapeutic index,re-hospitalization rate and cardiovascular event mortality in patients with Yang deficiency and flooding syndrome,so as to provide some clinical reference for optimizing the treatment strategy in vulnerable period.Method: This study was designed as a prospective,randomized controlled study.Heart failure patients who were discharged from the Department of Cardiology of the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine from July 2017 to October2018 were enrolled,patients who met the inclusion criteria were randomly divided into observation group and control group.Two groups of patients were treated with standardized drugs according to the Guidelines for Rational Use of Heart Failure 2016.The observation group was given 4 capsules of Qili Qiangxin Capsule on the basis of the control group,3times a day orally,for 12 weeks.The efficacy indexes before and after treatment,including non-invasive hemodynamic parameters,cardiac ultrasound(LVEF),plasma NT-proBNP level,6-minute walking test and Minnesota quality of life score,were compared between the two groups,and the incidence of re-admission due to deterioration of heart failure and death due to cardiovascular events during treatment was counted.The data results were statistically analyzed using SPSS 22.0 software.Result:1.There was no significant difference in age,sex,NYHA classification of cardiac function,underlying etiology,course of disease and the number of hospitalizations due to heart failure in the past 12 months between the observation group and the control group(P > 0.05).2.The re-hospitalization rate of the observation group was 3.33%,and that of the control group was 13.33%.There was no significant difference in the re-hospitalization rate between the two groups(P=0.161);there was no difference in the cardiogenic mortality rate between the observation group and the control group(3.33% VS.3.33%,P=1.000).3.After treatment,the levels of SV,SVI,CO,CI and CTI increased,HR,EDFR and SVR decreased,and the difference was statistically significant.The observation group SVI(82.80+5.31 VS.79.86 +5.45,P < 0.05),SVI(47.55 +3.30 VS.45.65 +3.65,P < 0.05),CO(5.68+0.30 VS.5.42 +0.36,P < 0.05),CI(3.27 +0.20 +0.15,P < 0.221,CTI.46).The improvement of <26.30 VS.197.85 +56.33,P<0.05),EDFR(48.49 +3.96 VS.51.07 +5.15,P<0.05),SVR(1118.31 +143.49 VS.1194.55 +141.96,P<0.05)was better than those of the control group.4.After treatment,the levels of NT-proBNP in both groups decreased significantly,and the observation group was better than the control group(241.69(+109.26 VS.303.03(+106.78,P< 0.05);after treatment,the LVEF of the two groups improved significantly,but there was no significant difference between the two groups(51.83(+2.83 VS.50.55(+3.28,P > 0.05).5.Minnesota living with heart failure questionnaire score of the two groups was lower than that before treatment,and the 6-minute walking test distance was longer.The observation group was superior to the control group in the improvement of walking distance(473.00+37.11 VS.449.76 +47.18,P<0.05)and quality of life(26.55 +3.66 VS.29.00 +3.47,P<0.05).Conclusion:On the basis of standardized western medicine treatment of heart failure,Qili Qiangxin capsule can improve hemodynamics,reduce left ventricular filling pressure,improve heart function,and improve quality of life and activity tolerance in patients with heart failure with Yang deficiency and water flooding syndrome.